Presentations to highlight new nonclinical data on product candidates, new technologies, innovations designed to shorten TIL manufacturing and clinical trials…
HUMMELSTOWN, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) -- SIRPant Immunotherapeutics Inc, a clinical-stage immuno-oncology company focusing on developing next-generation macrophage-based…
SAN FRANCISCO, CA and WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology…
The engagement is an additional step in the Company's path towards marketing clearance with the FDABRAINTREE, Mass., Sept. 27, 2023…
Qualigen Therapeutics, Inc. Figure 1A Qualigen Therapeutics, Inc. Figure 1B Qualigen Therapeutics, Inc. Table 1Two posters include data on potential clinical biomarkers…
Updated results from the BCMA/CD19 dual-targeted GC012F, including longer-term follow-up and three additional patients, presented at the International Myeloma Society…
Clinical trial evaluating the Company’s novel mRNA biomarkers demonstrated sensitivity for colorectal cancer of 94% with specificity of 97% and…
RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024FARMINGTON HILLS, Mich., and PITTSBURGH, Sept.…
BOSTON and LONDON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced…
WEST CHESTER, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology…